Immunogenicity and efficacy of DNA vaccines encoding influenza A proteins in aged mice

Vaccine

Volumn 16, Issue 18, 1998, Pages 1748-1755

  Bender, B S ^a,b   Ulmer, J B ^c   DeWitt, C M ^c   Cottey, R ^a   Taylor, S F ^a   Ward, A M ^a   Friedman, A ^a   Liu, M A ^c   Donnelly, J J ^c  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Aging; DNA vaccine; Influenza

Indexed keywords

BACTERIAL PROTEIN; DNA VACCINE; INFLUENZA VACCINE; VIRUS HEMAGGLUTININ; VIRUS NUCLEOPROTEIN;

AGE; ANIMAL EXPERIMENT; ARTICLE; BODY WEIGHT; CYTOTOXIC T LYMPHOCYTE; DRUG EFFICACY; FEMALE; HOST RESISTANCE; IMMUNE RESPONSE; IMMUNOASSAY; IMMUNOGENICITY; INFLUENZA VIRUS A; INTRANASAL DRUG ADMINISTRATION; LYMPHOCYTE ACTIVATION; MOUSE; NONHUMAN; PRIORITY JOURNAL;

AGING; ANIMALS; FEMALE; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; INFLUENZA A VIRUS; MICE; MICE, INBRED BALB C; NUCLEOPROTEINS; T-LYMPHOCYTES, CYTOTOXIC; VACCINES, DNA; VIRAL PROTEINS;

EID: 0032212385     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(98)00135-2     Document Type: Article

References (55)

1. 1 Ghendon, Y. The immune response of humans to live and inactivated influenza vaccines. Adv. Exp. Med. Biol. 1989, 257, 37-45.
2. 2 Small, P.A. Jr. Influenza: pathogenesis and host defense. Hasp. Pract. 1990, 25(51-4), 57-62.
3. 3 Meitin, C.A., Bender, B.S. and Small, P.A. Jr. Enteric immunization of mice against influenza with recombinant vaccinia. Proc. Natl. Acad. Sci. USA 1994, 91, 11187-11191.
4. 4 Renegar, K.B. and Small, P.A. Jr. Immunoglobulin A mediation of murine nasal anti-influenza virus immunity. J. Virol. 1991, 65, 2146-2148.
5. 5 Clements, M.L., Betts, R.F., Tierney, E.L. and Murphy, B.R. Serum and nasal wash antibodies associated with resistance to experimental challenge with influenza A wild-type virus. J. Clin. Microbiol. 1986, 24, 157-160.
6. 6 McMichael, A.J., Gotch, F.M., Noble, G.R. and Beare, P.A. Cytotoxic T-cell immunity to influenza. N. Engl. J. Med. 1983, 309, 13-17.
7. 7 Yap, K.L., Ada, G.L and McKenzie, I.F. Transfer of specific cytotoxic T lymphocytes protects mice inoculated with influenza virus. Nature 1978, 273, 238-239.
8. 8 Eichelberger, M., Allan, W., Zijlstra, M., Jaenisch, R. and Doherty, P.C. Clearance of influenza virus respiratory infection in mice lacking class I major histocompatibility complex-restricted CD8+ T cells. J. Exp. Med. 1991, 174, 875-880.
9. 9 Bender, B.S., Croghan, T., Zhang, L. and Small, P.A. Jr. Transgenic mice lacking class I major histocompatibility complex-restricted T cells have delayed viral clearance and increased mortality after influenza virus challenge. J. Exp. Med. 1992, 175, 1143-1145.
10. 10 Germain, R.N. and Marguiles, D.H. The biochemistry and cell biology of antigen processing and presentation. Annu. Rev. Immunol. 1993, 11, 403-450.
11. 11 Gross, P.A., Hermogenes, A.W., Sacks, H.S., Lau, J. and Levandowski, R.A. The efficacy of influenza vaccines in elderly persons. A meta-analysis and review of the literature. Ann. Interm. Med. 1995, 123, 518-527.
12. 12 Brody, J.A. and Brock, D.B. Epidemiological and statistical characteristics of the United States elderly population. In: Handbook of the Biology of Aging. Eds Finch, C.E. and Schneider, E.L. Van Nostrand Reinhold, New York, 1985, pp. 3-26.
13. 13 Centers for Disease Control. Prevention and Control of Influenza. MMWR 1990; 39(RR-7), 1-15.
14. 14 Bender, B.S., Johnson, M.P. and Small, P.A. Influenza in senescent mice: impaired cytotoxic T-lymphocyte activity is correlated with prolonged infection. Immun. 1991, 72, 514-519.
15. 15 Bender, B.S., Taylor, S.F., Zander, D.S. and Cottey, R. Pulmonary immune response of young and aged mice after influenza challenge. J. Lab. Clin. Med. 1995, 126, 169-177.
16. 16 Taylor, S.F., Cottey, R.J., Zander, D.S. and Bender, B.S. Influenza infection of β2-microglobulin deficient (β2m-/-) mice reveals a loss of CD4+ T cell functions with aging. J. Immunol. 1997, 159, 3453-3459.
17. 17 Powers, D.C. Influenza A virus-specific cytotoxic T lymphocyte activity declines with advancing age. J. Am. Geriatr. Soc. 1993, 41, 1-5.
18. 18 Bender, B.S. and Small, P.A. Jr. Heterotypic immune mice lose protection against influenza virus infection with senescence. J. Infect. Dis. 1993, 168, 873-880.
19. 19 Schulman, J.L. and Kilbourne, E.D. Induction of partial specific heterotypic immunity in mice by a single infection with influenza A virus. J. Exp. Med. 1965, 175, 170-174.
20. 20 Vetter, R.A., Lehrer, S., Ramphal, R. and Small, P.A. Jr. Outcome of influenza infection: effect of site of initial infection and heterotypic immunity. Infect. Immun. 1980, 29, 654-662.
21. 21 Vetter, R.A., Barber, W.H. and Small, P.A. Jr. Heterotypic immunity to influenza to ferrets. Infect Immun. 1980, 29, 650-653.
22. 22 Townsend, A.R.M., McMichael, A.J., Carter, N.P., Huddleston, J.A. and Brownlee, G.G. Cytotoxic T cell recognition of the influenza nucleoprotein and haemagglutini expressed in transfected mouse L cells. Cell 1984, 9, 13-25.
23. 23 Yewdell, J.W., Bennink, J.R., Smith, G.L. and Moss, B. Influenza A virus nucleoprotein is a major target antigen for cross-reactive anti-influenza A virus cytotoxic T lymphocytes. Proc. Natl. Acad. Sci. USA 1985, 82, 1785-1789.
24. 24 Gorman, O.T., Bean, W.J., Kawaoka, Y. and Webster, R.G. Evolution of the nucleoprotein gene of influenza A virus. J. Virol. 1990, 64, 1487-1497.
25. 25 McDonnell, W.M. and Askari, F.K. DNA vaccines. N. Engl. J. Med. 1996, 334, 42-45.
26. 26 Ulmer, J.B., Donnelly, J.J. and Parker, S.E. et al. Heterologous protection against influenza by injection of DNA encoding a viral protein. Science 1993, 259, 1745-1749.
27. 27 Ulmer, J.B., Deck, R.R., DeWitt, C.M., Friedman, A., Donnelly, J.J. and Liu, M.A. Protective immunity by intramuscular injection of low doses of influenza virus DNA vaccines. Vaccine 1994, 12, 1541-1544.
28. 28 Yankauckas, M.A., Morrow, J.E. and Parker, S.E. et al. Long-term anti-nucleoprotein cellular and humoral immunity is induced by intramuscular injection of plasmid DNA containing NP gene. DNA Cell. Biol. 1993, 12, 771-776.
29. 29 Webster, R.G., Fynan, E.F., Santoro, J.C. and Robinson, H. Protection of ferrets against influenza challenge with a DNA vaccine to the haemagglutinin. Vaccine 1994, 12, 1495-1498.
30. 30 Donnelly, J.J., Friedman, A. and Martinez, D. et al. Preclinical efficacy of a prototype DNA vaccine: enhanced protection against antigenic drift in influenza virus. Nat. Med. 1995, 1, 583-587.
31. 31 Liu, M.A., McClements, W., Ulmer, J.B., Shiver, J. and Donnelly, J. Immunization of non-human primates with DNA vaccines. Vaccine 1997, 15, 909-912.
32. 32 Fynan, E.F., Robinson, H.L. and Webster, R.G. Use of DNA encoding influenza haemagglutinin as an avian influenza vaccine. DNA Cell. Biol. 1993, 12, 785-789.
33. 33 Cox, G.J., Zamb, T.J. and Babiuk, L.A. Bovine herpesvirus 1: immune responses in mice and cattle injected with plasmid DNA. J. Virol. 1993, 67, 5664-5667.
34. 34 Deck, R.R., DeWitt, C.M., Donnelly, J.J., Liu, M.A. and Ulmer, J.B. Characterization of humoral immune responses induced by an influenza haemagglutinin DNA vaccine. Vaccine 1997, 15, 71-78.
35. 35 Montgomery, D.L., Shiver, J.W. and Leander, K.R. et al. Heterologous and homologous protection against influenza A by DNA vaccination: optimization of DNA vector. DNA Cell. Biol. 1993, 12, 777-783.
36. 36 Bender, B.S., Bell, W.E., Taylor, S. and Small, P.A. Jr. Class I major histocompatibility complex-restricted cytotoxic T lymphocytes are not necessary for heterotypic immunity to influenza. J. Infect. Dis. 1994, 170, 1195-1200.
37. 37 Donnelly, J.J., Friedman, A. and Martinez, D. et al. Preclinical efficacy of a prototype DNA vaccine: enhanced protection against antigenic drift in influenza virus. Nat. Med. 1995, 1, 583-587.
38. 38 Bender, B.S., Johnson, M.P., Flexner, C., Moss, B. and Small, P.A. Cytotoxic T-lymphocyte activity induced by influenza vaccination in young and aged mice. In: Vaccines 90. Modern Approaches to New Vaccines Including Prevention of AIDS. Eds Brown, F., Chanock, R., Ginsberg, H.S. and Lerner, R.A. Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, 1990, pp. 69-73.
39. 39 Effros, R.B. and Walford, R.L. The effect of age on the antigen-presenting mechanism in limiting dilution precursor cell frequency analysis. Cell. Immunol. 1984, 88, 531-539.
40. 40 Liang, S., Mozdzanowska, K., Palladino, G. and Gerhard, W. Heterosubtypic immunity to influenza type A virus in mice. Effector mechanisms and their longevity. J. Immunol. 1994, 152, 1653-1661.
41. 41 Epstein, S.L., Lo., C.Y., and Misplon, J.A. et al. Mechanisms of heterosubtypic immunity to lethal influenza A virus infection in fully immunocompetent, T cell-depleted beta2-microglobulin-deficient, and J chain-deficient mice. J. Immunol. 1997, 158, 1222-1230.
42. 42 Ulmer, J.B., Deck, R.R., Dewitt, C.M., Donnhly, J.I. and Liu, M.A. Generation of MHC class I-restricted cytotoxic T lymphocytes by expression of a viral protein in muscle cells: antigen presentation by non-muscle cells. Immunology 1996, 89, 59-67.
43. 43 Fu, T.M., Friedman, A., Ulmer, J.B., Liu, M.A. and Donnelly, J.J. Protective cellular immunity: cytotoxic T-lymphocyte responses against dominant and recessive epitopes of influenza virus nucleoprotein induced by DNA immunization. J. Virol. 1997, 71, 2715-2721.
44. 44 Imler, J.L. Adenovirus vectors as recombinant viral vaccines. Vaccine 1995, 13, 1143-1151.
45. 45 Dobber, R., Tielemans, M. and Nagelkerken, L. The in vivo effects of neutralizing antibodies against IFN-gamma, IL-4, or IL-10 on the humoral immune response in young and aged mice. Cell. Immunol. 1995, 160, 185-192.
46. 46 Mbawuike, I.N., Wyde, P.R. and Anderson, P.M. Enhancement of the protective efficacy of inactivated influenza A virus vaccine in aged mice by IL-2 liposomes. Vaccine 1990, 8, 347-352.
47. 47 Ben-Yehuda, A., Ehleiter, D., Hu, A.R. and Weksler, M.E. Recombinant vaccinia virus expressing the PR/8 infuenza haemagglutinin gene overcomes the impaired immune response and increased susceptibility of old mice to influenza infection. J. Infect. Dis. 1993, 168, 352-357.
48. 48 Beyer, W.E., Palache, A.M., Baljet, M. and Masurel, N. Antibody induction by influenza vaccines in the elderly: a review of the literature. Vaccine 1989, 7, 385-394.
49. 49 Renegar, K.B. and Small, P.A. Jr. Passive transfer of local immunity to influenza virus infection by IgA antibody. J. Immunol. 1991, 146, 1972-1978.
50. 50 Meitin, C.A., Bender, B.S. and Small, P.A. Jr. Influenza immunization: intranasal live vaccinia recombinant contrasted with parental inactivated vaccine. Vaccine 1991, 9, 751-756.
51. 51 Lawson, C.M., Bennink, J.R., Restifo, N.P., Yewdell, J.W. and Murphy, B.R. Primary pulmonary cytotoxic T lymphocytes induced by immunization with a vaccinia virus recombinant expressing influenza A virus nucleoprotein peptide do not protect mice against challenge. J. Virol. 1994, 68, 3505-3511.
52. 52 Sastry, K.J., Bender, B.S., Bell, W., Small, P.A. Jr. and Arlinghaus, R.B. Effects of influenza virus-specific cytotoxic T-lymphocyte responses induced by a synthetic nucleoprotein peptide on the survival of mice challenged with a lethal dose of virus. Vaccine 1994, 12, 1281-1287.
53. 53 Gao, X.M., Zheng, B., Liew, F.Y., Brett, S. and Tite, J. Priming of influenza virus-specific cytotoxic T lymphocytes in vivo by short synthetic peptides. J. Immunol. 1991, 147, 3268-3273.
54. 54 Tamura, S., Miyata, K. and Matsuo, K. et al. Acceleration of influenza virus clearance by Th1 cells in the nasal site of mice immunized intranasally with adjuvant-combined recombinant nucleoprotein. J. Immunol. 1996, 156, 3892-3900.
55. 55 Mbawuike, I.N., Acuna, C.L., Walz, K.C., Atmar, R.L, Greenberg, S.B. and Couch, R.B. Cytokines and impaired CD8+ CTL activity among elderly persons and the enhancing effect of 11-12. Mech. Ageing Dev. 1997, 94, 25-39.